Crossmark

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders

Crossref DOI link: https://doi.org/10.1186/s42466-021-00139-8

Published Online: 2021-08-06

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bayas, A.

Berthele, A. https://orcid.org/0000-0001-9650-6222
Hemmer, B.

Warnke, C.

Wildemann, B.
License Information

Text and Data Mining valid from 2021-08-06

Version of Record valid from 2021-08-06
More Information

Article History

Received: 23 June 2021

Accepted: 24 June 2021

First Online: 6 August 2021

Declarations

:

: n.a. (no human participants, human data or human tissue involved).

: n.a. (no individual person’s data in any form included).

: All authors are members of the panel responsible for the current revision and publication of the DGN S2k-Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. Regarding individual financial conflicts of interest, please refer to the “Leitlinienreport” to the respective S2k-Guideline (see )

Document is current

Any future updates will be listed below